Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Victor H. Jiménez-Zepeda"'
Autor:
Victor H. Jiménez-Zepeda, Patrick Yau, Douglas Stewart, Jowher Berhan, Carole Chambers, Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar Bahlis
Publikováno v:
Revista de Investigación Clínica, Vol 74, Iss 1 (2022)
Background: The impact of coronavirus disease-19 on the management of multiple myeloma (MM) has been recognized. However, the real effect on clinical outcomes remains poorly understood. Objective: We describe a local experience of the management of M
Externí odkaz:
https://doaj.org/article/24d22422a2b54a8095061b7749b6d767
Autor:
Ellen Lewis, Nowell Fine, Sylvia McCulloch, Jason Tay, Peter Duggan, Paola Neri, Nizar Bahlis, Victor H. Jimenez-Zepeda
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5608-5616 (2024)
Background: Pre-clinical and retrospective data suggest that doxycycline added to treatment regimens has benefit in AL amyloidosis. However, a recent multicenter, open-label, randomized controlled trial in AL amyloidosis patients treated with CyBorD
Externí odkaz:
https://doaj.org/article/3a06596a38654a66af102f797b94abb0
Autor:
Julie Côté, Richard LeBlanc, Hira Mian, Michael P. Chu, Arleigh McCurdy, Esther Masih-Khan, Jiandong Su, Victor H. Jimenez-Zepeda, Kevin Song, Martha Louzada, Darrell White, Michael Sebag, Anthony Reiman, Julie Stakiw, Rami Kotb, Debra Bergstrom, Muhammad Aslam, Rayan Kaedbey, Christopher P. Venner, Engin Gul, Donna Reece
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian Myeloma Research Group (CMRG) national database, we examined the details and outcom
Externí odkaz:
https://doaj.org/article/fb087ee0177d4902a6bafc2f90ec045f
Autor:
Arleigh McCurdy, Hira Mian, Richard LeBlanc, Victor H. Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece, Christopher P. Venner
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-6 (2023)
Abstract While most patients diagnosed with multiple myeloma (MM) receive initial therapy, reported attrition rates are high. Understanding attrition rates and characteristics of patients not receiving subsequent therapy is useful for MM stakeholders
Externí odkaz:
https://doaj.org/article/14c4decaca6e4a0bbfd717e2c08b1751
Autor:
Hira Mian, Richard LeBlanc, Martha Louzada, Esther Masih‐Khan, Arleigh McCurdy, Christopher P. Venner, Julie Stakiw, Moustafa Kardjadj, Victor H. Jimenez‐Zepeda, Michael Sebag, Darrell White, Muhammad Aslam, Kevin Song, Anthony Reiman, Rami Kotb, Engin Gul, Donna Reece
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4357-4362 (2023)
Abstract Using the Canadian Myeloma Research Group Database, a retrospective study of 167 newly diagnosed, transplant‐ineligible patients with multiple myeloma (MM) that received lenalidomide‐dexamethasone as front‐line treatment was conducted
Externí odkaz:
https://doaj.org/article/f086a93b14a2417f97d2b0f2547cfc26
Autor:
Arleigh McCurdy, Martha Louzada, Christopher P. Venner, Alissa Visram, Esther Masih‐Khan, Moustafa Kardjadj, Victor H. Jimenez‐Zepeda, Richard LeBlanc, Michael Sebag, Kevin Song, Darrell White, Hira Mian, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Rami Kotb, Engin Gul, Donna Reece
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1252-1261 (2022)
Abstract Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relaps
Externí odkaz:
https://doaj.org/article/1c70a968264b4965a924d97d53f6976e
Autor:
Victor H. Jimenez‐Zepeda, Donna Reece, Rodrigo Rigo, Priyanka Gogna, Shiying Kong, Xun Yang Hu, Parv Chapani, Winson Y. Cheung, Darren R. Brenner, Richard Plante, Kun Shi, Asad Husain, Dipti Tankala, Devon J. Boyne
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1262-1269 (2022)
Abstract Amyloid light chain (AL) amyloidosis is a rare and chronic bone marrow disorder. Existing claims data can be used to help understand the real‐world treatment patterns and outcomes of this patient population. Various population‐based admi
Externí odkaz:
https://doaj.org/article/8a03f5fca1404604871eed4b9fc80ec6
Autor:
Arleigh McCurdy, Hira Mian, Richard LeBlanc, Victor H. Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece, Christopher P. Venner
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/a0d9c78988334797b5fff861e80eb58a
Autor:
Arleigh McCurdy, Christopher P. Venner, Esther Masih-Khan, Martha Louzada, Richard LeBlanc, Michael Sebag, Kevin Song, Victor H. Jimenez-Zepeda, Rami Kotb, Moustafa Kardjadj, Hira Mian, Darrell White, Julie Stakiw, Muhammad Aslam, Anthony Reiman, Engin Gul, Donna Reece
Publikováno v:
Current Oncology, Vol 29, Iss 3, Pp 1575-1582 (2022)
The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently
Externí odkaz:
https://doaj.org/article/2aa83e8250b744b88779ba8b83e7bcb2
Autor:
Hira Mian, Christine Eisfeld, Christopher P. Venner, Esther Masih-Khan, Moustafa Kardjadj, Victor H. Jimenez-Zepeda, Cyrus Khandanpour, Georg Lenz, Arleigh McCurdy, Michael Sebag, Kevin Song, Richard LeBlanc, Darrell White, Julie Stakiw, Anthony Reiman, Martha Louzada, Muhammad Aslam, Rami Kotb, Engin Gul, Donna Reece
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundDaratumumab, a monoclonal antibody directed against CD38 is a recent class of drugs introduced into the multiple myeloma therapeutic landscape. While clinical trial data have shown a remarkable impact on outcomes, the efficacy of daratumuma
Externí odkaz:
https://doaj.org/article/1386edbe4b5c417785e99a1323900c9c